Article info
Correspondence response
Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci
- Correspondence to Dr Bente Glintborg, Department of Rheumatology, Gentofte and Herlev University Hospital, Hellerup 3500, Denmark; glintborg{at}dadlnet.dk
Citation
Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci
Publication history
- Received December 4, 2018
- Accepted December 5, 2018
- First published December 20, 2018.
Online issue publication
May 11, 2023
Article Versions
- Previous version (11 May 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.